These findings provide an internal validation of how specific phenotypic traits (levels of expression of mutant EGFR, activation of AKT-mTOR signaling, etc.)within a heterogeneous tumor are associated with levels of sensitivity to treatment in NSCLCs. This evidence concerns the gene MTOR and neoplasm.